This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Pirisudanol
A pyridoxine-pyroglutamate ester nootropic formerly marketed in Europe that enhances cholinergic and GABAergic neurotransmission for age-related cognitive decline.
Benefits
What is Pirisudanol?
Pirisudanol (marketed under brand names Nadex, Stivane, and Mentis) is a nootropic compound that consists of a pyridoxine (vitamin B6) ester linked to pyroglutamic acid. This dual molecular structure allows it to act on multiple neurotransmitter systems simultaneously, particularly the cholinergic and GABAergic pathways. Developed and marketed primarily in European countries including France, Germany, and Italy during the 1970s and 1980s, Pirisudanol was prescribed for age-related cognitive decline, memory impairment, post-stroke cognitive rehabilitation, and attention disorders. Clinical trials conducted during this period demonstrated improvements in memory, attention, and psychomotor speed in elderly patients with mild to moderate cognitive impairment.
The pharmacological rationale for Pirisudanol lies in its ability to deliver two neuroactive compounds - pyridoxine and pyroglutamic acid - that work synergistically to support cognitive function. Pyridoxine is an essential cofactor in the synthesis of several neurotransmitters including GABA, dopamine, serotonin, and norepinephrine, while pyroglutamic acid (also known as pidolic acid or 5-oxoproline) is a naturally occurring amino acid derivative involved in glutamate metabolism and the gamma-glutamyl cycle. Clinical studies, including double-blind placebo-controlled trials published in journals such as Neuropsychobiology and Current Medical Research and Opinion, reported that Pirisudanol at doses of 300-600 mg daily significantly improved cognitive test scores compared to placebo in patients with organic brain syndrome. Although withdrawn from some European markets, it remains a compound of interest in nootropic research.
- Cholinergic enhancement: Increases acetylcholine release in cortical and hippocampal regions by providing pyridoxine as a cofactor for choline acetyltransferase, the enzyme responsible for acetylcholine synthesis
- GABAergic modulation: Supports GABA synthesis through pyridoxine's role as a cofactor for glutamic acid decarboxylase (GAD), the rate-limiting enzyme in GABA production, thereby improving inhibitory neurotransmission
- Pyroglutamate-mediated glutamatergic effects: The pyroglutamic acid moiety participates in the gamma-glutamyl cycle and may modulate glutamatergic neurotransmission, supporting learning and memory processes
- Monoamine synthesis support: Pyridoxine serves as a cofactor for aromatic amino acid decarboxylase, which is essential for the synthesis of dopamine, serotonin, and norepinephrine
- Cerebral metabolism improvement: Enhances overall cerebral energy metabolism by supporting mitochondrial enzyme function and improving glucose utilisation in neuronal tissue
- Standard clinical dose: 300-600 mg per day, typically divided into two or three doses taken with meals
- Starting dose: 100-200 mg taken twice daily, with gradual upward titration over 1-2 weeks based on tolerance
- Post-stroke rehabilitation: Higher doses up to 600 mg daily were used in clinical settings for post-stroke cognitive recovery
- Duration of treatment: Clinical trials typically ran for 8-12 weeks, with some studies extending to 6 months of continuous use
- Administration: Oral tablets or capsules, taken with food to improve absorption and reduce gastrointestinal side effects
- Generally well-tolerated: Clinical trials reported a favourable safety profile with most adverse effects being mild and transient, including occasional nausea, headache, and mild gastrointestinal discomfort
- Market withdrawal context: Withdrawn from some European markets not primarily due to safety concerns but rather due to insufficient evidence meeting updated regulatory standards for efficacy
- Vitamin B6 accumulation: Long-term high-dose use carries theoretical risk of peripheral neuropathy associated with excessive pyridoxine intake, though clinical doses are generally well below toxic thresholds
- Drug interactions: May interact with levodopa (reducing its efficacy) and other drugs metabolised by pyridoxine-dependent pathways; caution advised with concurrent B6 supplementation
- Contraindications: Should be avoided in patients with known hypersensitivity to pyridoxine or pyroglutamic acid; not recommended during pregnancy or lactation due to lack of safety data
Natural Sources & Forms
- Clinical trial evidence: Bompani and Scali (1986) - double-blind placebo-controlled trial of Pirisudanol in elderly patients with cognitive decline, published in Neuropsychobiology
- Pharmacological profile: Ban (1975) - "Psychopharmacology for the Aged" reviewing the mechanisms of Pirisudanol and related nootropics in Current Medical Research and Opinion
- Pyroglutamate cognition research: Grioli et al. (1990) - "Pyroglutamic acid improves the age associated memory impairment" in Fundamental and Clinical Pharmacology
- European regulatory history: Documentation from French and German pharmaceutical registries regarding the marketing authorisation and withdrawal of Pirisudanol-containing products
- Nootropic classification: Giurgea and Salama (1977) - classification of nootropic drugs including Pirisudanol in the broader context of cognitive enhancers
Frequently Asked Questions
A pyridoxine-pyroglutamate ester nootropic formerly marketed in Europe that enhances cholinergic and GABAergic neurotransmission for age-related cognitive decline.
The key benefits of Pirisudanol include: Anxiety & Calm, Cognitive Enhancement, Energy, Focus, Memory, Mood.
Cholinergic enhancement: Increases acetylcholine release in cortical and hippocampal regions by providing pyridoxine as a cofactor for choline acetyltransferase, the enzyme responsible for acetylcholine synthesis GABAergic modulation: Supports GABA synthesis through pyridoxine's role as a cofactor for glutamic acid decarboxylase (GAD), the rate-limiting enzyme in GABA production, thereby improving inhibitory neurotransmission Pyroglutamate-mediated glutamatergic effects: The pyroglutamic acid moiety participates in the gamma-glutamyl cycle and may modulate glutamatergic neurotransmission, supporting learning and memory processes Monoamine synthesis support: Pyridoxine serves as a cofactor for aromatic amino acid decarboxylase, which is essential for the synthesis of dopamine, serotonin, and norepinephrine Cerebral metabolism improvement: Enhances overall cerebral energy metabolism by supporting mitochondrial enzyme function and improving glucose utilisation in neuronal tissue
Standard clinical dose: 300-600 mg per day, typically divided into two or three doses taken with meals Starting dose: 100-200 mg taken twice daily, with gradual upward titration over 1-2 weeks based on tolerance Post-stroke rehabilitation: Higher doses up to 600 mg daily were used in clinical settings for post-stroke cognitive recovery Duration of treatment: Clinical trials typically ran for 8-12 weeks, with some studies extending to 6 months of continuous use Administration: Oral tablets or capsules, taken with food to improve absorption and reduce gastrointestinal side effects
Generally well-tolerated: Clinical trials reported a favourable safety profile with most adverse effects being mild and transient, including occasional nausea, headache, and mild gastrointestinal discomfort Market withdrawal context: Withdrawn from some European markets not primarily due to safety concerns but rather due to insufficient evidence meeting updated regulatory standards for efficacy Vitamin B6 accumulation: Long-term high-dose use carries theoretical risk of peripheral neuropathy associated with excessive pyridoxine intake, though clinical doses are generally well below toxic thresholds Drug interactions: May interact with levodopa (reducing its efficacy) and other drugs metabolised by pyridoxine-dependent pathways; caution advised with concurrent B6 supplementation Contraindications: Should be avoided in patients with known hypersensitivity to pyridoxine or pyroglutamic acid; not recommended during pregnancy or lactation due to lack of safety data
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!